<DOC>
	<DOCNO>NCT01159379</DOCNO>
	<brief_summary>The purpose study ass cross-reactivity tolerability ertapenem patient IgE-mediated allergy least one beta-lactam molecule .</brief_summary>
	<brief_title>Safety Ertapenem Beta-lactam Allergic Patients .</brief_title>
	<detailed_description>Ertapenem new carbapenem , stable dehydropeptidase broad antibacterial activity . Ertapenem exhibit bactericidal mode action long half-life 4.5 hour ; reason develop single daily dose carbapenem . In literature , case IgE-mediated allergy ertapenem describe . However , single study put evidence 47 % rate cross-reactivity imipenem-cilastatin beta-lactams group patient affect IgE-mediated allergy drug . For reason carbapenem administration beta-lactam allergic patient always consider potentially harmful . Other study report low cross-reactivity rate ( 7 11 % ) imipenem-cilastatin beta-lactams patient study undergo allergy test order demonstrate pathogenesis reaction . Recent study put evidence imipenem low cross-reactivity rate beta-lactams good tolerability among patient IgE-mediated allergy beta-lactams : Romano et al . find cross-reactivity rate 0.9 % imipenem penicillins 112 penicillin-allergic patient ( mean age 44.56 ± 15.66 y . ) ; Atanasković-Marković et al . find cross-reactivity rate 0.8 % 124 paediatric patient ( age range 3-14 y . ) imipenem penicillin . In group imipenem well tolerated patient negative allergy test . Meropenem show good tolerability penicillin allergic patient : Romano et al . find cross-reactivity rate 0.9 % penicillin meropenem penicillin-allergic patient ( mean age 47.83 ± 15.8 ) ; Atanasković-Marković et al . find cross-reactivity rate 0.8 % 109 paediatric patient ( age range 3-14 y . ) meropenem penicillin . In group meropenem well tolerated patient negative allergy test . No data regard cross-reactivity ertapenem beta-lactams tolerability among patient IgE-mediated allergy beta-lactams available literature . Aim study On basis data , decide investigate cross-reactivity ertapenem beta-lactams patient suffer IgE-mediated allergy least one beta-lactam molecule tolerability group patient negative allergy test ertapenem .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Hypersensitivity , Immediate</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<mesh_term>beta-Lactams</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>IgEmediated allergy least one betalactam molecule positive allergy test ertapenem chronic disease treatment betablockers pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>IgE-mediated allergy</keyword>
	<keyword>Beta-lactams</keyword>
	<keyword>Ertapenem</keyword>
	<keyword>Cross-reactivity</keyword>
	<keyword>Immediate-type skin test</keyword>
	<keyword>Intravenous tolerance test</keyword>
</DOC>